Drug intelligence / Profile preview

atropine + scopolamine

Development stage
Unknown
Lead developer
Fresenius Kabi
Modality
Small Molecules
Administration
Intravenous, Intramuscular, Subcutaneous, Oral, Ophthalmic
01

Overview

atropine + scopolamine is a pharmacological combination of two naturally occurring tropane alkaloids found in plants of the Solanaceae family. Both agents function as competitive antagonists at muscarinic acetylcholine receptors (M1 through M5), effectively blocking the action of the neurotransmitter acetylcholine in the central and peripheral nervous systems. Atropine is primarily utilized for its ability to increase heart rate and reduce smooth muscle spasms, while scopolamine (also known as hyoscine) is distinguished by its potent central nervous system effects, including sedation and the prevention of motion-induced nausea. Clinically, this combination is employed as a pre-anesthetic medication to inhibit salivary and bronchial secretions and to prevent bradycardia during surgery. It is also used in palliative care to manage excessive respiratory secretions and in the treatment of various gastrointestinal motility disorders.

Brand names
Atropine and Scopolamine
Other names
atropine and scopolamineatropine and hyoscinehyoscine and atropine
02

Targets

CHRM3 (M3)CHRM2 (M2)HTR3A (5-hydroxytryptamine receptor 3A)M1 (Muscarinic acetylcholine receptor M1)

Beyond the preview

Go deeper on atropine + scopolamine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on atropine + scopolamine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call